Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.39 |
| ▸ | FAP | Q12884 | 6/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23733475 | 1.00 | DPP4 (0.39) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL20203569 | 0.84 | CDK1 (0.40) | HSP90AA1HSP90B1TLR9TLR8TLR7 | |
| SCHEMBL20203529 | 0.82 | CDK1 (0.45) | DPP4DPP8DPP9HSP90AA1HSP90B1 | |
| SCHEMBL23733474 | 0.82 | CDK1 (0.45) | DPP4DPP8DPP9HSP90AA1HSP90B1 | |
| SCHEMBL23733478 | 0.81 | CDK1 (0.43) | DPP4DPP8DPP9HSP90AA1HSP90B1 | |
| SCHEMBL20203643 | 0.79 | HSP90AA1 (0.40) | HSP90AA1HSP90B1CDK4CDK2CDK6 | |
| SCHEMBL23733483 | 0.79 | CDK4 (0.35) | HSP90AA1HSP90B1CDK4CDK2CDK6 | |
| SCHEMBL20203531 | 0.77 | TLR9 (0.41) | HSP90AA1HSP90B1TLR9TLR8TLR7 | |
| SCHEMBL20203431 | 0.77 | KEAP1 (0.41) | HSP90AA1HSP90B1TLR9TLR8TLR7 | |
| SCHEMBL20203457 | 0.77 | GRM5 (0.49) | HSP90AA1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| WO-2018097297-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | DPP4 316/4885FAP 1552/4885DPP8 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.